Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XG-102 for post-cataract surgery inflammation and pain
NCT02508337Phase 3Completed
- Sponsor
- Xigen
- Start
- Jul 2015
- Primary completion
- Jan 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of brimapitide in post-operative ocular inflammation, post-operative ocular pain, sponsored by Xigen. Started Jul 2015; status: completed.
02
Drugs
brimapitide
03
Conditions
post-operative ocular inflammationpost-operative ocular pain
Beyond the preview
Go deeper on NCT02508337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508337.